Skip to main content
SpringerLink
Log in

Cost of severe SLE substantial in Canada

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by GlaxoSmithKline plc.

Reference

  • Clarke AE, et al. Costs associated with severe and non-severe SLE in Canada. Arthritis care and research : 3 Sep 2014. Available from: URL: http://doi.org/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cost of severe SLE substantial in Canada. PharmacoEcon Outcomes News 712, 12 (2014). https://doi.org/10.1007/s40274-014-1557-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1557-9

Search

Navigation